Joining Cynata as Chief Medical Officer in October 2021, Dr Jolanta Airey sat down with ValiantCEO for International Women’s Day to discuss her motivations, her career journey to date and her advice for women in STEM. If you’d like to be inspired, the full interview is here:
In late February, Cynata received a notice of Decision to Grant from the State Intellectual Property Office of the People’s Republic of China (SIPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell (MSC) technology (scroll to after the table):
With COVID shining a light on the importance of innovation in medicine with a focus on unmet needs, read Ross’ view on the work being done to improve the effectiveness of drugs and treatments, and to reduce their side effects:
CEO Dr Ross Macdonald joined ausbiz to discuss the development and the outlook for Cynata in 2022 following the receipt of a patent from Japan, the world’s second largest stem cell market.
Providing hope for people with diabetic foot ulcers (DFU), Cynata’s Phase I trial of CYP‑006TK has commenced and is now open for patient enrolment: